Bangalore – OneSource Specialty Pharma Limited (BSE:5442S2, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended June 30, 2026.
Financial Highlights (In ₹ million)
| Particulars | Q1FY27 | Q4FY26 | QoQ | Q1FY26 | YoY |
| Revenues | 4,490 | 4,282 | 5% | 3,273 | 37% |
| EBITDA | 1,233 | 919 | 34% | 885 | 39% |
| EBITDA % | 27.5% | 21.5% | 600bps | 27.0% | 43bps |
| Adjusted PAT | 637 | 390 | 63% | 371 | 72% |
| Adjusted EPS | 5.6 | 3.4 | 63% | 3.2 | 71% |
Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Ǫ1FY27: ₹43m, Ǫ4FY2c: gain ₹0.3m, Ǫ1FY2c: ₹2Sm) and scheme related intangible amortisation (₹344m in each quarter)
Mr. Neeraj Sharma, CEO s MD, OneSource Specialty Pharma Limited speaking on the performance said, “We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Ǫ2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.”
